<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04197167</url>
  </required_header>
  <id_info>
    <org_study_id>0122-19-HYMC</org_study_id>
    <nct_id>NCT04197167</nct_id>
  </id_info>
  <brief_title>Mid-Infrared Spectroscopy as a Real Time Diagnostic Tool for Chronic Endometritis</brief_title>
  <official_title>Mid-Infrared Spectroscopy as a Real Time Diagnostic Tool for Chronic Endometritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hillel Yaffe Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hillel Yaffe Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Investigator propose to develop an in-vitro technique for the measurement and analysis of
      freshly excised biopsies during hysteroscopy procedure in patients with suspected Chronic
      Endometritis (CE) condition. Furthermore, the investigator propose to develop a
      discrimination model between the CE and inflammatory CE types using the measured
      spectroscopic data from freshly excised biopsies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is common practice that, following hysteroscopy, the clinician needs to wait for about two
      weeks before the results of the histology are returned and the clinical treatment is
      initiated. In this research, the investigator intent to show that the mid infrared ATR
      (Assisted Reproductive Treatment) spectroscopy method will provide the physician with
      sufficient information about the CE inflammation status in a considerably shorter period of
      time to allow immediate initiation of the appropriate treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 12, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single Group Assignment</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of infrared spectroscopy (ATR-FTIR technique) with routine histopathology</measure>
    <time_frame>2 Years</time_frame>
    <description>Using ATR-FTIR technique of impression smears obtained from CE tissue during standard hysteroscopy procedure will provide a new diagnostic tool for fast diagnosis of CE inflammation and thus assist in the clinical decision process leading to assisted reproductive treatment (ART).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Endometritis</condition>
  <condition>IVF</condition>
  <arm_group>
    <arm_group_label>Women undergoing hysteroscopy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients scheduled to undergo hysteroscopy for the evaluation of abnormal bleeding or abnormal cervical or uterine findings.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hysteroscopy</intervention_name>
    <description>Diagnostic procedure</description>
    <arm_group_label>Women undergoing hysteroscopy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Infrared Spectroscopy</intervention_name>
    <description>This device uses spectral absorption of the tissue taken during hysteroscopy to determine immediate diagnosis of Chronic Endometritis</description>
    <arm_group_label>Women undergoing hysteroscopy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients scheduled to undergo hysteroscopy for the evaluation of abnormal bleeding or
             abnormal cervical or uterine findings.

          -  Patients scheduled for any histological evaluation including endometrial biopsy,
             dilatation and curettage (D&amp;C), biopsy/excision of uterine polyp or fibroid or any
             other cervical or uterine lesion.

          -  Age 18 and over.

        Exclusion Criteria:

          -  Pregnant women, minors and lack of judgment women will not included

          -  At the request of the examined woman
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Einat Shalom-Paz, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hillel Yaffe Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Einat Shalom-Paz, Prof</last_name>
    <phone>+972-47744750</phone>
    <email>EinatS@hy.health.gov.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Asaf Bilgory, MD</last_name>
    <email>asaf_bil@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hillel Yaffe Medical Center</name>
      <address>
        <city>Hadera</city>
        <zip>3810101</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Osnat Palgi, BSc.</last_name>
      <phone>+972-47744602</phone>
      <email>osnatp@hymc.gov.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>December 4, 2019</study_first_submitted>
  <study_first_submitted_qc>December 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2019</study_first_posted>
  <last_update_submitted>February 18, 2020</last_update_submitted>
  <last_update_submitted_qc>February 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

